28 results on '"Karrison, T"'
Search Results
2. Pharmacodynamic (PD) assessment of blood pressure (BP) in a randomized dose-ranging trial of sorafenib (S).
3. A randomized phase II study of pazopanib in castrate-sensitive prostate cancer: A University of Chicago phase II consortium/DoD Prostate Cancer Clinical Trials Consortium study.
4. Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response.
5. Detection of combinations of cytogenetic abnormalities in chronic lymphocytic leukemia (CLL) by fluorescent in situ hybridization (FISH) probes.
6. Use of typical in-patient blood pressure measurements to detect bevacizumab-induced elevation in systolic pressure after the first infusion.
7. VEGF pathway therapy: Resampling positive phase III data to assess phase II trial designs and endpoints.
8. Effect of coadministration of statins on neutropenia in a phase I genotype-directed dose-escalation study of irinotecan.
9. A phase II trial of gemcitabine(G), capecitabine (C), and bevacizumab (B) in patients (pts) with metastatic renal cell carcinoma (RCC)
10. Effects of vascular endothelial growth factor (VEGF) signaling inhibition on human erythropoiesis
11. Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E)
12. Refining epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR) phenotypes with a cetuximab (C) monotherapy stage of a phase II trial for non-small cell lung cancer (NSCLC)
13. Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC)
14. Randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevazicumab (BFHX) in intermediate stage head and neck cancer (HNC)
15. pKDR/KDR ratio predicts response in a phase I/II pharmacodynamic study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer (HNC)
16. Dyamic contrast enhanced MRI (DCE-MRI) pharmacodynamic (PD) study of sorafenib in metastatic renal cell carcinoma (RCC): Results of a randomized, phase II trial
17. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
18. A phase I study of G3139 in combination with RICE chemotherapy in relapsed non-Hodgkin’s lymphoma (NHL)
19. Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway
20. A prospective pharmacogenomic (PG), pharmacodynamic (PD), and pharmacokinetic (PK) study of determinants of erlotinib toxicity
21. Performance and side effect evaluation of sequentially reduced radiotherapy doses in a phase II trial of induction chemotherapy (IndCT) followed by concomitant chemoradiotherapy (CTX) for advanced head and neck cancer (HNC)
22. A phase II study of Epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin’s lymphomas
23. A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM)
24. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC)
25. A randomized phase II trial of Interleukin-2 in combination with four different doses of bryostatin in patients with renal cell carcinoma
26. The impact of induction chemotherapy on subsequent concurrent chemoradiotherapy (CRT) related side effects, function & quality of life (QOL) in head and neck cancer (HNC)
27. The impact of induction chemotherapy on subsequent concurrent chemoradiotherapy (CRT) related side effects, function & quality of life (QOL) in head and neck cancer (HNC)
28. A randomized phase II trial of Interleukin-2 in combination with four different doses of bryostatin in patients with renal cell carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.